Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation followed by adebrelimab and chemotherapy for oligoprogressive NSCLC after first-line immunotherapy
ChiCTR2600119287Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: progression-free survival. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600119287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119287.